Compare SpaceX (SPCX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SpaceX vs Viatris Inc — how do they compare? SpaceX trades at $142.6 (market cap $1.93T), while Viatris Inc trades at $16.1 (market cap $18.49B). The key difference: SpaceX is far larger — about 104.4× Viatris Inc's market cap, and Viatris Inc pays a 2.98% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| SPCX | VTRS | |
|---|---|---|
Market Cap | $1.93T | $18.49B |
Sector | Technology | Health |
52-Week High | $202.09 | $17.86 |
52-Week Low | $108.27 | $9.49 |
Enterprise Value | $1.87T | $30.61B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPCX stock surged 9.7% to $146.22, reflecting strong momentum after a post-IPO lockup expiry rally. Technical indicators show a bullish trend with support at $139 and resistance at $151. The company reported Q2 2026 earnings beat but maintains negative net margins, with revenue growth driven by AI and space segments. Analyst consensus is overwhelmingly bullish with an $228.52 price target, though high valuations and capex intensity pose risks.
Outlook: Growth potential is high from AI expansion and SpaceX's market leadership, but profitability challenges and volatile post-IPO trading require caution. Risks include elevated P/S ratio, negative cash flow from investing, and competitive pressures in the space sector.
Viatris (VTRS) trades at $16.04, down 1.47% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.69 exceeding expectations by 14.8%. Recent FDA approval for Gwyn Lo contraceptive patch and divestiture of Tyrvaya nasal spray demonstrate strategic portfolio optimization. Revenue trends show stabilization after declining from $16.3B in 2022 to $14.3B in 2025, with 2026 projections at $14.7B.
While Viatris shows operational strength with consistent cash flow generation and debt reduction, the company faces profitability challenges with negative net income margins and elevated P/E ratio of 236.2. Analyst sentiment is cautiously optimistic with 30.8% buy ratings, though the majority (61.5%) recommend hold. Key risks include ongoing margin pressure, generic drug pricing headwinds, and execution of strategic initiatives amid competitive pharmaceutical landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
